Kryger Capital LLC Makes New $3.09 Million Investment in Drugs Made In America Acquisition II Corp. $DMII

Kryger Capital LLC acquired a new stake in shares of Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 309,729 shares of the company’s stock, valued at approximately $3,088,000.

Several other institutional investors have also made changes to their positions in DMII. Magnetar Financial LLC purchased a new position in shares of Drugs Made In America Acquisition II in the fourth quarter worth approximately $26,730,000. Glazer Capital LLC purchased a new stake in shares of Drugs Made In America Acquisition II in the 4th quarter valued at approximately $23,264,000. First Trust Capital Management L.P. purchased a new stake in shares of Drugs Made In America Acquisition II in the 4th quarter valued at approximately $20,474,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in Drugs Made In America Acquisition II in the 1st quarter worth approximately $19,960,000. Finally, Hudson Bay Capital Management LP acquired a new position in Drugs Made In America Acquisition II in the 4th quarter worth approximately $19,493,000.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Weiss Ratings raised shares of Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (e+)” rating in a research note on Thursday, June 11th. Wall Street Zen raised Drugs Made In America Acquisition II from a “sell” rating to a “hold” rating in a research report on Sunday, May 10th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Drugs Made In America Acquisition II currently has a consensus rating of “Sell”.

Drugs Made In America Acquisition II Stock Performance

NASDAQ:DMII opened at $10.10 on Friday. Drugs Made In America Acquisition II Corp. has a fifty-two week low of $9.86 and a fifty-two week high of $10.11. The firm’s 50-day simple moving average is $10.08.

Drugs Made In America Acquisition II Profile

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank?check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply?chain resiliency and related healthcare operations in the United States.